Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction

American Journal of Cardiology

Volumn 111, Issue 6, 2013, Pages 914-918

  Pride, Yuri B ^a   Piccirillo, Bryan J ^a   Gibson, C Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AUTOPSY; CARDIOVASCULAR MAGNETIC RESONANCE; ELECTROCARDIOGRAPHY; HEART INFARCTION; HUMAN; INCIDENCE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884212746     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.11.042     Document Type: Review

References (49)

1. J.S. Alpert, K. Thygesen, E. Antman, and J.P. Bassand Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 36 2000 959 969
2. J.G. Canto, M.G. Shlipak, W.J. Rogers, J.A. Malmgren, P.D. Frederick, C.T. Lambrew, J.P. Ornato, H.V. Barron, and C.I. Kiefe Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain JAMA 283 2000 3223 3229
3. J.B. Herrick Clinical features of sudden obstruction of the coronary arteries JAMA 59 1912 2015 2022
4. D. Aguilar, S.Z. Goldhaber, D.J. Gans, A.S. Levey, J.G. Porush, J.B. Lewis, J.L. Rouleau, T. Berl, E.J. Lewis, and M.A. Pfeffer Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy Am J Cardiol 94 2004 337 339
5. A. Boland, J. Gerardy, D. Mossay, D. Delapierre, and V. Seutin Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition Br J Pharmacol 135 2002 713 720
6. T.M. Davis, P. Fortun, J. Mulder, W.A. Davis, and D.G. Bruce Silent myocardial infarction and its prognosis in a community-based cohort of type 2 diabetic patients: the Fremantle Diabetes Study Diabetologia 47 2004 395 399
7. A. de Torbal, E. Boersma, J.A. Kors, G. van Herpen, J.W. Deckers, D.A. van der Kuip, B.H. Stricker, A. Hofman, and J.C. Witteman Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study Eur Heart J 27 2006 729 736
8. R.H. Grimm Jr., S. Tillinghast, K. Daniels, J.D. Neaton, S. Mascioli, R. Crow, M. Pritzker, and R.J. Prineas Unrecognized myocardial infarction: experience in the Multiple Risk Factor Intervention Trial (MRFIT) Circulation 75 1987 II6 II8
9. L.S. Jonsdottir, N. Sigfusson, H. Sigvaldason, and G. Thorgeirsson Incidence and prevalence of recognised and unrecognised myocardial infarction in women: the Reykjavik Study Eur Heart J 19 1998 1011 1018
10. W.B. Kannel Prevalence and clinical aspects of unrecognized myocardial infarction and sudden unexpected death Circulation 75 1987 II4 II5
11. W.B. Kannel, and R.D. Abbott Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study N Engl J Med 311 1984 1144 1147
12. W.B. Kannel, L.A. Cupples, and D.R. Gagnon Incidence, precursors and prognosis of unrecognized myocardial infarction Adv Cardiol 37 1990 202 214
13. W.B. Kannel, P.M. McNamara, M. Feinleib, and T.R. Dawber The unrecognized myocardial infarction: fourteen-year follow-up experience in the Framingham study Geriatrics 25 1970 75 87
14. J.R. Margolis, W.S. Kannel, M. Feinleib, T.R. Dawber, and P.M. McNamara Clinical features of unrecognized myocardial infarction - silent and symptomatic: eighteen year follow-up: the Framingham study Am J Cardiol 32 1973 1 7
15. J.H. Medalie, and U. Goldbourt Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors Ann Intern Med 84 1976 526 531
16. J. Nadelmann, W.H. Frishman, W.L. Ooi, D. Tepper, S. Greenberg, H. Guzik, E.J. Lazar, M. Heiman, and M. Aronson Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: the Bronx Aging Study Am J Cardiol 66 1990 533 537
17. R.H. Rosenman, M. Friedman, C.D. Jenkins, R. Straus, M. Wurm, and R. Kositchek Clinically unrecognized myocardial infarction in the Western Collaborative Group Study Am J Cardiol 19 1967 776 782
18. S.E. Sheifer, B.J. Gersh, N.D. Yanez III, P.A. Ades, G.L. Burke, and T.A. Manolio Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly J Am Coll Cardiol 35 2000 119 126
19. M.G. Shlipak, D.A. Elmouchi, D.M. Herrington, F. Lin, D. Grady, and M.A. Hlatky The incidence of unrecognized myocardial infarction in women with coronary heart disease Ann Intern Med 134 2001 1043 1047
20. E. Sigurdsson, G. Thorgeirsson, H. Sigvaldason, and N. Sigfusson Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris: the Reykjavik Study Ann Intern Med 122 1995 96 102
21. J. Stokes III, and T.R. Dawber The silent coronary: the frequency and clinical characteristics of unrecognized myocardial infarction in the Framingham study Ann Intern Med 50 1959 1359 1369
22. K. Yano, and C.J. MacLean The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program Arch Intern Med 149 1989 1528 1532
23. D.C. Burgess, D. Hunt, L. Li, D. Zannino, E. Williamson, T.M. Davis, M. Laakso, Y.A. Kesaniemi, J. Zhang, R.W. Sy, S. Lehto, S. Mann, and A.C. Keech Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Eur Heart J 31 2010 92 99
24. W.B. Kannel, P. Sorlie, and P.M. McNamara Prognosis after initial myocardial infarction: the Framingham study Am J Cardiol 44 1979 53 59
25. K.A. Ammar, J.A. Kors, B.P. Yawn, and R.J. Rodeheffer Defining unrecognized myocardial infarction: a call for standardized electrocardiographic diagnostic criteria Am Heart J 148 2004 277 284
26. K.A. Ammar, B.P. Yawn, L. Urban, D.W. Mahoney, J.A. Kors, S. Jacobsen, and R.J. Rodeheffer Identification of optimal electrocardiographic criteria for the diagnosis of unrecognized myocardial infarction: a population-based study Ann Noninvasive Electrocardiol 10 2005 197 205
27. R.J. Prineas, R.S. Crow, and H. Blackburn The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification 1982 Wright PSG Boston
28. H.V. Pipberger, E. Simonson, E.A. Lopez Jr., M.A. Araoye, and H.A. Pipberger The electrocardiogram in epidemiologic investigations: a new classification system Circulation 65 1982 1456 1464
29. S.E. Sheifer, T.A. Manolio, and B.J. Gersh Unrecognized myocardial infarction Ann Intern Med 135 2001 801 811
30. C.K. Chow What is the significance of unrecognized non-Q-wave myocardial infarction? PLoS Med 6 2009 e1000060
31. D.W. Kehl, R. Farzaneh-Far, B. Na, and M.A. Whooley Prognostic value of electrocardiographic detection of unrecognized myocardial infarction in persons with stable coronary artery disease: data from the Heart and Soul Study Clin Res Cardiol 100 2011 359 366
32. M.J. Leening, S.E. Elias-Smale, J.F. Felix, J.A. Kors, J.W. Deckers, A. Hofman, B.H. Stricker, and J.C. Witteman Unrecognised myocardial infarction and long-term risk of heart failure in the elderly: the Rotterdam Study Heart 96 2010 1458 1462
33. B.R. Chaitman, R.M. Hardison, D. Adler, S. Gebhart, M. Grogan, S. Ocampo, G. Sopko, J.A. Ramires, D. Schneider, and R.L. Frye The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction Circulation 120 2009 2529 2540
34. K.A. Ammar, S. Samee, R. Makwana, L. Urban, D.W. Mahoney, J.A. Kors, M.M. Redfield, S. Jacobsen, and R.J. Rodeheffer Echocardiographic characteristics of electrocardiographically unrecognized myocardial infarctions in a community population Am J Cardiol 96 2005 1069 1075
35. K.A. Ammar, R. Makwana, M.M. Redfield, J.A. Kors, J.C. Burnett Jr., and R.J. Rodeheffer Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study Am Heart J 151 2006 799 805
36. K.A. Ammar, R. Makwana, S.J. Jacobsen, J.A. Kors, J.C. Burnett Jr., M.M. Redfield, B.P. Yawn, and R.J. Rodeheffer Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography Ann Noninvasive Electrocardiol 12 2007 27 37
37. D. Aguilar The clinically unrecognized Q-wave myocardial infarction: what does it mean and what should we do? Am Heart J 151 2006 768 770
38. R.J. Kim, D.S. Fieno, T.B. Parrish, K. Harris, E.L. Chen, O. Simonetti, J. Bundy, J.P. Finn, F.J. Klocke, and R.M. Judd Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function Circulation 100 1999 1992 2002
39. R.J. Kim, T.S. Albert, J.H. Wible, M.D. Elliott, J.C. Allen, J.C. Lee, M. Parker, A. Napoli, and R.M. Judd Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial Circulation 117 2008 629 637
40. R.Y. Kwong, and H. Korlakunta Diagnostic and prognostic value of cardiac magnetic resonance imaging in assessing myocardial viability Top Magn Reson Imaging 19 2008 15 24
41. C.M. Kramer Detecting unrecognized myocardial infarction: the importance of imaging Curr Cardiol Rep 12 2010 3 5
42. C.J. Cox Return to normal of the electrocardiogram after myocardial infarction Lancet 1 1967 1194 1197
43. J.M. Murabito, M.G. Larson, S.T. Lin, J.C. Evans, and D. Levy Unexplained gradual-onset Q wave patterns: a case series from the Framingham Study J Electrocardiol 28 1995 267 275
44. R.Y. Kwong, A.K. Chan, K.A. Brown, C.W. Chan, H.G. Reynolds, S. Tsang, and R.B. Davis Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease Circulation 113 2006 2733 2743
45. R.Y. Kwong, H. Sattar, H. Wu, G. Vorobiof, V. Gandla, K. Steel, S. Siu, and K.A. Brown Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction Circulation 118 2008 1011 1020
46. H.W. Kim, I. Klem, D.J. Shah, E. Wu, S.N. Meyers, M.A. Parker, A.L. Crowley, R.O. Bonow, R.M. Judd, and R.J. Kim Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease PLoS Med 6 2009 e1000057
47. D.A. Morrow, E. Braunwald, M.P. Bonaca, S.F. Ameriso, A.J. Dalby, M.P. Fish, K.A. Fox, L.J. Lipka, X. Liu, J.C. Nicolau, A.J. Ophuis, E. Paolasso, B.M. Scirica, J. Spinar, P. Theroux, S.D. Wiviott, J. Strony, and S.A. Murphy Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
48. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
49. H.H. Paring, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Eng J Med 345 2001 870 878